CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
NOVATO, Calif., Nov. 08, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
- Shalini Sharp, the company’s Chief Financial Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8, 2016 at 2:30pm MT in Scottsdale, AZ.
- Tom Kassberg, the company's Chief Business Officer, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 1:30pm ET in New York, NY.
The live and archived webcasts of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replays will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
